XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Leases, Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Commitments And Contingencies [Line Items]        
Research and development expense $ 66,170,000 $ 73,320,000 $ 124,226,000 $ 136,930,000
CyDex License Agreement [Member]        
Commitments And Contingencies [Line Items]        
Research and development expense     1,000,000.0  
CyDex License Agreement [Member] | First and Second Clinical Development Milestones [Member] | Brexanolone [Member] | Maximum [Member]        
Commitments And Contingencies [Line Items]        
Expected milestone payments 800,000   800,000  
CyDex License Agreement [Member] | First and Second Regulatory Milestones [Member] | Brexanolone [Member] | Maximum [Member]        
Commitments And Contingencies [Line Items]        
Expected milestone payments 3,800,000   3,800,000  
CyDex License Agreement [Member] | Third and Fourth Clinical Development Milestones [Member] | Brexanolone [Member] | Maximum [Member]        
Commitments And Contingencies [Line Items]        
Expected milestone payments 1,300,000   1,300,000  
CyDex License Agreement [Member] | Third and Fourth Regulatory Milestones [Member] | Brexanolone [Member] | Maximum [Member]        
Commitments And Contingencies [Line Items]        
Expected milestone payments 8,500,000   8,500,000  
CyDex License Agreement [Member] | Clinical Development [Member] | Brexanolone [Member]        
Commitments And Contingencies [Line Items]        
Research and development expense related to milestone expense     0  
Milestone payments     0  
Milestone payments related to intangible assets     0  
CyDex License Agreement [Member] | Clinical Development [Member] | SAGE-689 [Member] | Maximum [Member]        
Commitments And Contingencies [Line Items]        
Expected milestone payments 800,000   800,000  
CyDex License Agreement [Member] | Regulatory Milestones [Member] | Brexanolone [Member]        
Commitments And Contingencies [Line Items]        
Research and development expense related to milestone expense     0  
Milestone payments     0  
Intangible asset related to milestone   $ 0   0
Milestone payments related to intangible assets     0 $ 0
CyDex License Agreement [Member] | Regulatory Milestones [Member] | SAGE-689 [Member] | Maximum [Member]        
Commitments And Contingencies [Line Items]        
Expected milestone payments 1,800,000   1,800,000  
CyDex License Agreement [Member] | Clinical Development and Regulatory Milestones [Member]        
Commitments And Contingencies [Line Items]        
Research and development expense related to milestone expense     3,600,000  
Milestone payments     3,600,000  
Intangible asset related to milestone $ 3,000,000.0   $ 3,000,000.0